Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03980717 · ClinicalTrials.gov registry record · NA

Fetal Endotracheal Occlusion (FETO) in the Resolution of Pulmonary Hypertension in Fetuses With Severe CDH

A NA study of Congenital Diaphragmatic Hernia, sponsored by Michael A Belfort.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT03980717 is a NA study of Congenital Diaphragmatic Hernia that is actively recruiting participants, run by Michael A Belfort. The registered enrollment target is 80 participants, below the 193-participant average among 22 other Congenital Diaphragmatic Hernia trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03980717, a NA study of Congenital Diaphragmatic Hernia, is actively recruiting participants, sponsored by Michael A Belfort.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

Congenital diaphragmatic hernia (CDH) occurs when the diaphragm fails to fully fuse and leaves a portal through which abdominal structures can migrate into the thorax. In the more severe cases, the abdominal structures remain in the thoracic cavity and compromise the development of the lungs. Infants born with this defect have a decreased capacity for gas exchange; mortality rates after birth have been reported between 40-60%. Now that CDH can be accurately diagnosed by mid-gestation, a number of strategies have been developed to repair the hernia and promote lung tissue development. Fetal tracheal occlusion (FETO), using a fetoscopically delivered and removed balloon device, has been used to temporarily occlude the trachea and increase lung distension in CDH to allow the lungs to develop and has been shown to increase survival at birth. The role of FETO in the resolution of pulmonary hypertension in fetuses with severe left- and right- sided CDH remains unclear. Our recent observation that FETO is associated with a higher proportion of infants who resolve their pulmonary hypertension by the age of 1 year as compared with those who have not had FETO, is based on a retrospective cohort study, which, as with any such design, has some intrinsic limitations. Thus, a prospective cohort study that is appropriately powered to confirm or disprove this encouraging observation is needed. If our preliminary observation is confirmed, resolution of PH by the age of 1 year could be added to the benefits of the FETO procedure in severe left and right-sided CDH cases. The investigators will perform 40 FETO procedures on fetuses diagnosed prenatally with severe right- or left-sided CDH, and outcome data will be compared with that of a control group of severe right- or left-sided CDH who will not undergo the FETO procedure because of medical or social issues. Because the prevalence of left-sided CDH is higher than right-side CDH, the investigators will perform 25 FETO procedures in

Interventions

  • DEVICE Goldbal Detachable Balloon and delivery microcatheter

Study Locations (1)

Texas

  • Texas Childrens Hospital - Houston

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2019-08-09
Est. Completion 2030-12
Phase NA

Sponsor

Michael A Belfort

4 total trials

What the Registry Record Tells You About NCT03980717

The ClinicalTrials.gov registry entry for NCT03980717 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 22 other Congenital Diaphragmatic Hernia trials with a reported enrollment target (59% lower). The listed sponsor is Michael A Belfort, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Congenital Diaphragmatic Hernia appearing as the primary indexed condition, and to 1 intervention - of which Goldbal Detachable Balloon and delivery microcatheter is the first listed.

NCT03980717 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03980717 about?

NCT03980717 is a clinical study titled "Fetal Endotracheal Occlusion (FETO) in the Resolution of Pulmonary Hypertension in Fetuses With Severe CDH". Congenital diaphragmatic hernia (CDH) occurs when the diaphragm fails to fully fuse and leaves a portal through which abdominal structures can migrate into the thorax. In the more severe cases, the abdominal structures remain in the thoracic cavity and compromise the development of the lungs. Infant...

What is the current status of trial NCT03980717?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2019-08-09. Estimated completion is 2030-12.

What conditions does trial NCT03980717 study?

This clinical trial studies the following conditions: Congenital Diaphragmatic Hernia.

What interventions are being tested in trial NCT03980717?

The interventions under investigation include: Goldbal Detachable Balloon and delivery microcatheter (DEVICE).

Who is sponsoring clinical trial NCT03980717?

This trial is sponsored by Michael A Belfort, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03980717 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congenital Diaphragmatic Hernia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.